Big pharma, Partnering, Pharma

Iroko signs pharma licensing deal with Aspen

Posted on 29 October 2014

Tags: , ,

Iroko Pharmaceuticals signed a licensing agreement with Aspen Pharma for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand.

Aspen Pharma will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.

Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S., where ZORVOLEX is approved by the United States Food and Drug Administration for the management of mild to moderate acute pain and osteoarthritis pain.

ZORVOLEX is not currently approved for marketing in any other country.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply